Electronic health records can be valuable predictor of those likeliest to die from COVID

February 04, 2021

BOSTON - Medical histories of patients collected and stored in electronic health records (EHR) can be rapidly leveraged to predict the probability of death from COVID-19, information that could prove valuable in managing limited therapeutic and preventive resources to combat the devastating virus, researchers from Massachusetts General Hospital (MGH) have found. In a study published in npj Digital Medicine, the team described how artificial intelligence (AI) technology enabled it to identify factors such as age, history of pneumonia, gender, race and comorbidities like diabetes and cancer as predictors of poor outcomes in COVID-19 patients.

"By combining computational methods and clinical expertise, we developed a set of models to forecast the most severe COVID-19 outcomes based on past medical records, and to help understand the differences in risk factors across age groups," says co-lead author Hossein Estiri, PhD, an investigator in the Laboratory of Computer Science at MGH and an assistant professor of Medicine at Harvard Medical School (HMS). "Many prior studies have isolated small subsets of EHR data from after the infection, but ours is the first and largest to use entire historical medical records to try to untangle the role of age as the most important risk factor for COVID adverse outcomes."

The analytics/medical team drew on the COVID-19 "datamart" that had been created by hospital system Mass General Brigham for research, a repository of frequently refreshed longitudinal data on COVID-19 patients from across the system. Using electronic medical records from more than 16,000 such patients, the MGH team applied a computational algorithm -- with a human expert in the loop -- to identify 46 clinical conditions representing potential risk factors for death after a COVID-19 infection. "Despite relying on only previously documented demographics and comorbidities, our models demonstrated performance comparable to more complex prognostic models requiring an assortment of symptoms, laboratory values and images gathered at the time of diagnosis or during the course of the illness," notes Zachary Strasser, MD, co-lead author and postdoctoral fellow at MGH.

The MGH study found age to be the most important predictor of mortality in COVID-19 patients. A history of pneumonia was also identified by the study as a significant risk factor, as were histories of diabetes with complications, and cancer (particularly breast and prostate) among COVID-19 patients between the ages of 45 and 65. In patients between 65 and 85, diseases affecting the pulmonary system -- including interstitial lung disorders, chronic obstructive pulmonary disease (COPD), lung cancer, and a history of smoking - were strong predictors of poor outcomes. Comorbidities registering the highest odds ratios for death irrespective of age were chronic kidney disease, heart failure, abdominal aortic aneurysm, hypertension and aortic valve disease.

As for gender, the study found females to be at lower risk of death from COVID-19. Even after adjusting for age and chronic diseases, the researchers learned that women benefited from an unknown form of underlying protection against the worst outcome of the viral infection. In their overall model, researchers did not find evidence that a certain race or ethnicity altered the odds of mortality after contracting COVID-19. They did find in the oldest cohort of patients, however, that being African American was associated with a higher chance of mortality.

The sheer volume of EHR information and its marriage to predictive analytics becomes particularly important during a pandemic when access to large-scale, clinical trial grade data is not practical, emphasizes Shawn Murphy, MD, PhD, senior author and chief research informatics officer at Mass General Brigham. "The ability to quickly utilize data that has already been collected across the country to compute individual-level risk scores," he says, "is crucial for effectively allocating and distributing resources, including prioritizing vaccination among the general population."
-end-
The researchers are from the MGH Laboratory of Computer Science; the Department of Biomedical Informatics at HMS; and the MGH Department of Neurology.

The study was supported by the National Human Genome Research Institute and the National Library of Medicine.

About the Massachusetts General Hospital

Massachusetts General Hospital, founded in 1811, is the original and largest teaching hospital of Harvard Medical School. The Mass General Research Institute conducts the largest hospital-based research program in the nation, with annual research operations of more than $1 billion and comprises more than 9,500 researchers working across more than 30 institutes, centers and departments. In August 2020, Mass General was named #6 in the U.S. News & World Report list of "America's Best Hospitals."

Massachusetts General Hospital

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.